Autonomyo granted for its connected exoskeleton

Autonomyo exoskeleton © 2021 Autonomyo

Autonomyo exoskeleton © 2021 Autonomyo

Founded in 2021, Autonomyo has developed an exoskeleton equipped with motion-assist technology and connected to a digital platform that allows patients' progress to be monitored remotely. The Tech Seed loan granted by the Foundation for Technological Innovation (FIT) will allow the startup to finance the product further development after its first clinical trial in collaboration with the CHUV.

Nearly 60% of individuals who suffer a stroke leave rehabilitation clinics with major disabilities. For a long time, physicians believed that brain recovery happens only in the first months following the injury. However, it has been shown that the brain can relearn certain motor tasks even years after a stroke has occurred. This relearning is long and tedious as patients require months of daily exercise to recover their motor skills. In a context where hospital stays are very expensive, insurance companies often do not cover extended stays and therefore patients do not benefit from sufficient training intensity to recover their motor skills.

To combat motor disability, Autonomyo combines intensive training during the hospital stay with continuous rehabilitation at home. To this end, the startup has developed an exoskeleton connected to a digital training platform that allows doctors to monitor patients remotely and thus guarantee optimal follow-up. Using sensors, the exoskeleton adjusts to the patient's abilities and provides adaptive movement assistance to improve and accelerate recovery. Equipped with artificial intelligence technology, the digital platform provides training suggestions to patients based on their progress. To protect its unique technology, the EPFL startup from the EPFL Biorobotics Laboratory (BioRob) has filed two patents, one in the US and one in Europe.

The two co-founders of Autonomyo – Fabian Bischof and Dr Amalric Ortlieb – benefit from a close collaboration with EPFL and CHUV (Dr Mohamed Bouri, Prof. Andrea Serino, MED Stefano Carda), in addition to the support of associations against neuromuscular diseases ASRIMM and FSRMM and the Swiss MS society. The first clinical study will be finalized in early 2022.

Thanks to the Tech Seed loan from FIT, Autonomyo will be able to improve its solution based on the users’ feedback and propose a whole digital platform for patients, therapists and rehabilitation clinics. By 2022, Autonomyo hopes to finalise its solution by refining the requirements of its digital platform and its exoskeleton. From 2023, the startup hopes to market its solution in Switzerland and Europe.